Anktiva Receives Conditional Approval Recommendation in EU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2026
0mins
Should l Buy IBRX?
Source: stocktwits
- EU Approval Progress: In December 2025, the European Medicines Agency (EMA) recommended a conditional marketing authorization for Anktiva in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), facilitating early access to a medicine that addresses an unmet medical need.
- FDA Resubmission Plans: ImmunityBio is eyeing the resubmission of its application for Anktiva in BCG-unresponsive NMIBC with papillary tumors, despite a previous refuse to file letter from the FDA, indicating ongoing efforts to advance the drug's market entry.
- Positive Market Reaction: ImmunityBio (IBRX) shares have gained 79% over the past 12 months, and while retail sentiment on Stocktwits remains bearish, investors are showing strong interest in the potential approval of Anktiva, with expectations for a decision as early as next Monday.
- Investor Confidence Boosted: Some investors have increased their holdings in IBRX after seeing a price dip, believing that Anktiva's approval will lead to significant stock price appreciation, reflecting market optimism about the drug's prospects and ImmunityBio's future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.700
Low
5.00
Averages
7.33
High
9.00
Current: 7.700
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anktiva's New Data Sparks Attention Amid Psychedelic Push
- Trump's Policy Support: Founder Patrick Soon-Shiong stated that Trump “can make huge advances in transforming the health of Americans” following a White House push for psychedelic therapy research, potentially enhancing Anktiva's market acceptance.
- Breast Cancer Recurrence Risk Data: Soon-Shiong highlighted evidence linking lymphopenia to over a 2x increased risk of recurrence in early-stage breast cancer patients, emphasizing the importance of monitoring lymphocyte counts, which could drive clinical applications of related treatments.
- Post-COVID Immune Function Research: Plans for further clinical trials are underway to explore whether post-COVID immune dysfunction associated with T-cell exhaustion can be reversed, with Anktiva, an IL-15-based immunotherapy, potentially playing a key role in this process.
- Improved Market Sentiment: Following the news, retail sentiment for IBRX shifted from 'bearish' to 'neutral', with message volumes increasing by 70% over the week, indicating growing investor confidence in Anktiva's future potential.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor concerns over potential fraud.
- Allegations: The complaint alleges that the defendants materially overstated Anktiva's capabilities and failed to disclose adverse facts regarding the company's business and prospects, which could severely undermine investor confidence and lead to significant stock price volatility.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, indicating active participation and protection of their rights in the legal process.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, aiming to restore investor capital and ensure corporate accountability, thereby enhancing overall market integrity.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, resulting in investor losses when the truth emerged, highlighting significant transparency and compliance issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record rather than relying on intermediaries, ensuring they receive the best representation in the class action to protect their rights.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, minimizing the financial burden on investors.
- Case Background: The lawsuit alleges that executives of ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth was revealed, highlighting significant inaccuracies regarding the company's business and prospects.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, particularly regarding significant misrepresentations about Anktiva's capabilities, which may have resulted in investor losses exceeding $50,000.
- Lawsuit Context: A complaint filed on March 26, 2026, alleges that ImmunityBio and its executives, including Soon-Shion, materially overstated Anktiva's capabilities, leading to materially false and misleading statements about the company's business and prospects throughout the relevant period.
- Investor Rights Protection: Attorney Andrea Farah stated that the investigation focuses on whether the company and its executives provided investors with accurate and complete information, aiming to protect investors' legal rights.
- Law Firm Background: Lowey Dannenberg is a national law firm representing institutional and individual investors who have suffered financial losses due to corporate fraud and malfeasance, boasting significant experience in prosecuting multi-million-dollar lawsuits.
See More
Anktiva's New Data Sparks Attention Amid Psychedelic Push
- Trump's Policy Support: Founder Patrick Soon-Shiong stated that Trump “can make huge advances in transforming the health of Americans” following a White House push for psychedelic therapy research, potentially enhancing Anktiva's market acceptance.
- Breast Cancer Recurrence Risk Data: Soon-Shiong highlighted evidence linking lymphopenia to over a 2x increased risk of recurrence in early-stage breast cancer patients, emphasizing the importance of monitoring lymphocyte counts, which could drive clinical applications of related treatments.
- Post-COVID Immune Function Research: Plans for further clinical trials are underway to explore whether post-COVID immune dysfunction associated with T-cell exhaustion can be reversed, with Anktiva, an IL-15-based immunotherapy, potentially playing a key role in this process.
- Improved Market Sentiment: Following the news, retail sentiment for IBRX shifted from 'bearish' to 'neutral', with message volumes increasing by 70% over the week, indicating growing investor confidence in Anktiva's future potential.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor concerns over potential fraud.
- Allegations: The complaint alleges that the defendants materially overstated Anktiva's capabilities and failed to disclose adverse facts regarding the company's business and prospects, which could severely undermine investor confidence and lead to significant stock price volatility.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, indicating active participation and protection of their rights in the legal process.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, aiming to restore investor capital and ensure corporate accountability, thereby enhancing overall market integrity.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, resulting in investor losses when the truth emerged, highlighting significant transparency and compliance issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record rather than relying on intermediaries, ensuring they receive the best representation in the class action to protect their rights.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, minimizing the financial burden on investors.
- Case Background: The lawsuit alleges that executives of ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth was revealed, highlighting significant inaccuracies regarding the company's business and prospects.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, particularly regarding significant misrepresentations about Anktiva's capabilities, which may have resulted in investor losses exceeding $50,000.
- Lawsuit Context: A complaint filed on March 26, 2026, alleges that ImmunityBio and its executives, including Soon-Shion, materially overstated Anktiva's capabilities, leading to materially false and misleading statements about the company's business and prospects throughout the relevant period.
- Investor Rights Protection: Attorney Andrea Farah stated that the investigation focuses on whether the company and its executives provided investors with accurate and complete information, aiming to protect investors' legal rights.
- Law Firm Background: Lowey Dannenberg is a national law firm representing institutional and individual investors who have suffered financial losses due to corporate fraud and malfeasance, boasting significant experience in prosecuting multi-million-dollar lawsuits.
See More
